Promising Research Results Point to Potential Cures for Two Most Common Forms of CMT
By: Keith Fargo, Ph.D., Chief Scientific Officer Momentum is building in the development of gene therapies for Charcot-Marie-Tooth disease. Landmark back-to-back research publications offer innovative approaches to potentially curing the two most common forms of CMT....
Turning $128,000 into Millions to Deliver a Treatment for CMT
If you’ve ever been frustrated by the slow pace of research progress or questioned how a single donation makes a difference, the collaboration between the CMT Research Foundation and DTx Pharma proves that one simple action, one bold move and one donation is all...
Additional Funding Announced for Promising Gene Silencing Approach to Treat CMT1A
In January 2019, the CMT Research Foundation began funding a research project led by Dr. Kleopas Kleopa at the Cyprus Institute of Neurology & Genetics to study a gene therapy approach to lower levels of PMP22 protein, which is the protein coded for by the gene...
CMT Research Foundation Launches Groundbreaking Research to Overcome Barriers to Delivering CMT Therapies to the Peripheral Nervous System
Collaboration with World-Renowned Researcher Dr. James Dahlman Aims to Identify Lipid Nanoparticles for Peripheral Nervous System Delivery Using High-Throughput Screening One of the most significant challenges in Charcot-Marie-Tooth drug development is delivering...AcuraStem Scientists Demonstrate Positive Early Results for CMT2A Treatment
By: Keith N. Fargo, Ph.D., Chief Scientific Officer, CMT Research Foundation The CMT Research Foundation is currently funding a research project led by AcuraStem aimed at producing effective treatments for CMT2A. Using stem cells derived from adult patients, AcuraStem...
Important Research News Announcements
- Macrophages influence Schwann cell myelin autophagy after nerve injury and in a model of Charcot-Marie-Tooth disease May 20, 2023
- TGFβ4 alleviates the phenotype of Charcot-Marie-Tooth disease type 1A May 5, 2023
- DGIST Professor Minseok Kim’s team develops an electronic medicine technology that restores abnormal protein behavior, the cause of Charcot-Marie-Tooth Disease (CMT) March 31, 2023
- Charcot-Marie-Tooth neuropathies: current gene therapy advances and the route towards translation March 25, 2023
- MFN2-dependent recruitment of ATAT1 coordinates mitochondria motility with alpha-tubulin acetylation and is disrupted in CMT2A March 17, 2023
- Boosting peripheral BDNF rescues impaired in vivo axonal transport in CMT2D mice March 16, 2023
- Restoring Neurofilaments to Axons in a Mouse Model of CMT2E March 1, 2023
- Full-length isoform sequencing for resolving the molecular basis of Charcot-Marie-Tooth 2A February 8, 2023
- Torin1 restores proliferation rate in Charcot-Marie-Tooth disease type 2A cells harbouring MFN2 (mitofusin 2) mutation February 3, 2023
- Novel Variants in MPV17, PRX, GJB1 , and SACS Cause Charcot-Marie-Tooth and Spastic Ataxia of Charlevoix-Saguenay Type Diseases January 30, 2023